China Approves 59 Innovative Drugs in 2026 as Shanghai Leads Biopharma Licensing Deals
At the 2026 Zhangjiang Pharma Valley Conference and Shanghai International Biopharma Industry Week, figures showed China has approved 59 innovative drugs so far in 2026, 13 of them with new mechanisms or targets. Nationwide biopharma business development deals reached 113 in January-August 2026, worth USD 119.997 billion. Shanghai accounted for 37 deals, or 33% of the total, ranking first in the country.
The 2026 Zhangjiang Pharma Valley Conference and Shanghai International Biopharma Industry Week were held in Shanghai.
Since the start of 2026, China has approved 59 innovative drugs for market launch, 13 of which are drugs with new mechanisms and new targets.
In January-August 2026, there were 113 biopharma business development (BD) deals nationwide, with a total value of USD 119.997 billion.
Over the same period, Shanghai recorded 37 biopharma BD deals, accounting for 33% of the national total and ranking first in the country.
Why this event matters
The event has a measured impact on 3 industrys. The strongest current signal is positive for Pharmaceuticals, with intensity 70/100 and 75% confidence over a medium term horizon.
Pharmaceuticals
- Direction
- positive
- Intensity
- 70
- Confidence
- 75%
- Horizon
- Medium term
Biotechnology
- Direction
- positive
- Intensity
- 65
- Confidence
- 70%
- Horizon
- Medium term
Pharmaceutical R&D Services
- Direction
- positive
- Intensity
- 60
- Confidence
- 70%
- Horizon
- Short term
Impact figures are analytical estimates that combine direction, intensity, confidence and event importance. They are not investment advice.